194 related articles for article (PubMed ID: 29474501)
1. Risk assessment and HbA1c measurement in Norwegian community pharmacies to identify people with undiagnosed type 2 diabetes - A feasibility study.
Risøy AJ; Kjome RLS; Sandberg S; Sølvik UØ
PLoS One; 2018; 13(2):e0191316. PubMed ID: 29474501
[TBL] [Abstract][Full Text] [Related]
2. Diabetes risk assessments and HbA1c-measurements in community pharmacies.
Risøy AJ; Kjome RLS; Sandberg S; Sølvik UØ
Int J Pharm Pract; 2023 Sep; 31(5):512-519. PubMed ID: 37527496
[TBL] [Abstract][Full Text] [Related]
3. Pharmacists' experience of a diabetes risk-assessment service and analytical quality control in community pharmacies - A focus-group study.
Risøy AJ; Skeide Kjome RL; Svensberg K; Råheim M; Sølvik UØ
Res Social Adm Pharm; 2021 Jul; 17(7):1259-1266. PubMed ID: 34155978
[TBL] [Abstract][Full Text] [Related]
4. Quality Control of Norwegian Pharmacy HbA1c Testing: A Modest Beginning.
Ørvim Sølvik U; Risøy AJ; Kjome RLS; Sandberg S
J Diabetes Sci Technol; 2018 Jul; 12(4):753-761. PubMed ID: 29619895
[TBL] [Abstract][Full Text] [Related]
5. Diabetes and cardiovascular disease risk screening model in community pharmacies in a developing primary healthcare system: a feasibility study.
Alzubaidi HT; Chandir S; Hasan S; McNamara K; Cox R; Krass I
BMJ Open; 2019 Nov; 9(11):e031246. PubMed ID: 31712336
[TBL] [Abstract][Full Text] [Related]
6. Pharmacy Diabetes Screening Trial: protocol for a pragmatic cluster-randomised controlled trial to compare three screening methods for undiagnosed type 2 diabetes in Australian community pharmacy.
Krass I; Carter R; Mitchell B; Mohebbi M; Shih STF; Trinder P; Versace VL; Wilson F; Namara KM
BMJ Open; 2017 Dec; 7(12):e017725. PubMed ID: 29284715
[TBL] [Abstract][Full Text] [Related]
7. Participant and GP perspectives and experiences of screening for undiagnosed type 2 diabetes in community pharmacy during the Pharmacy Diabetes Screening Trial.
Krass I; Twigg MJ; Mitchell B; Wilson F; Mohebbi M; Trinder P; Shih STF; Carter R; Versace VL; McNamara K
BMC Health Serv Res; 2023 Dec; 23(1):1337. PubMed ID: 38041094
[TBL] [Abstract][Full Text] [Related]
8. Assessment of a screening protocol for type 2 diabetes in community pharmacy. The DiabNow Study.
Fikri-Benbrahim N; Martínez-Martínez F; Saéz-Benito L; Luque BS; Corpas JP; Moullin JC; Sabater-Hernández D
Diabetes Res Clin Pract; 2015 Jun; 108(3):e49-52. PubMed ID: 25819481
[TBL] [Abstract][Full Text] [Related]
9. Pharmacy diabetes screening trial (PDST): Outcomes of a national clustered RCT comparing three screening methods for undiagnosed type 2 diabetes (T2DM) in community pharmacy.
Krass I; Carter R; Mitchell B; Mohebbi M; Shih STF; Trinder P; Versace VL; Wilson F; Mc Namara KP
Diabetes Res Clin Pract; 2023 Mar; 197():110566. PubMed ID: 36738834
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of a novel pharmacy screening intervention to address the burden of type 2 diabetes and cardiovascular disease in an Arabic-speaking country.
Alzubaidi H; Hasan S; Saidawi W; Mc Namara K; Chandir S; Krass I
Diabet Med; 2021 Aug; 38(8):e14598. PubMed ID: 33969536
[TBL] [Abstract][Full Text] [Related]
11. Alcohol brief intervention in community pharmacies: a feasibility study of outcomes and customer experiences.
Khan NS; Norman IJ; Dhital R; McCrone P; Milligan P; Whittlesea CM
Int J Clin Pharm; 2013 Dec; 35(6):1178-87. PubMed ID: 24013957
[TBL] [Abstract][Full Text] [Related]
12. Improving pharmaceutical practice in diabetes care using point-of-care glycated haemoglobin testing in the community pharmacy.
Santana CR; de Oliveira MGG; Camargo MS; Moreira PMB; de Castro PR; Aguiar EC; Mistro S
Int J Pharm Pract; 2024 Feb; 32(1):46-51. PubMed ID: 37936510
[TBL] [Abstract][Full Text] [Related]
13. Opportunistic screening for type 2 diabetes in community pharmacies. Results from a region-wide experience in Italy.
Gnavi R; Sciannameo V; Baratta F; Scarinzi C; Parente M; Mana M; Giaccone M; Cavallo Perin P; Costa G; Spadea T; Brusa P
PLoS One; 2020; 15(3):e0229842. PubMed ID: 32187210
[TBL] [Abstract][Full Text] [Related]
14. Diabetes care in Norwegian pharmacies: a descriptive study.
Kjome RL; Sandberg S; Granås AG
Pharm World Sci; 2008 Apr; 30(2):191-8. PubMed ID: 17891470
[TBL] [Abstract][Full Text] [Related]
15. Involving the public and other stakeholders in development and evaluation of a community pharmacy alcohol screening and brief advice service.
Krska J; Mackridge AJ
Public Health; 2014 Apr; 128(4):309-16. PubMed ID: 24713598
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of a collaborative diabetes screening campaign between community pharmacies and general practitioners.
Murteira R; Cary M; Galante H; Romano S; Guerreiro JP; Rodrigues AT
Prim Care Diabetes; 2023 Aug; 17(4):314-320. PubMed ID: 37156696
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of a New Opportunistic Screening Strategy for Walk-in Fingertip HbA
Shono A; Kondo M; Hoshi SL; Okubo R; Yahagi N
Diabetes Care; 2018 Jun; 41(6):1218-1226. PubMed ID: 29686159
[TBL] [Abstract][Full Text] [Related]
18. COPD case finding by spirometry in high-risk customers of urban community pharmacies: a pilot study.
Castillo D; Guayta R; Giner J; Burgos F; Capdevila C; Soriano JB; Barau M; Casan P;
Respir Med; 2009 Jun; 103(6):839-45. PubMed ID: 19200706
[TBL] [Abstract][Full Text] [Related]
19. Opportunistic Risk Screening for Type 2 Diabetes: Exploring of Application of Diabetes Risk Assessment Tool in Community Pharmacy in Australia and Thailand.
Thoopputra T; Pongmesa T; Newby DA; Schneider J; Li SC
Value Health Reg Issues; 2016 May; 9():1-7. PubMed ID: 27881250
[TBL] [Abstract][Full Text] [Related]
20. A drop-in clinic for patients with poorly-controlled diabetes: a community pharmacy feasibility study.
Twigg MJ; Bhattacharya D; Desborough JA; Wright D
Int J Clin Pharm; 2015 Apr; 37(2):395-402. PubMed ID: 25666943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
